Journal Article
. 2021 Dec; 40(7):762-771.
doi: 10.1200/JCO.21.02067.

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

David M O'Malley 1 Maryna Neffa 2 Bradley J Monk 3 Tamar Melkadze 4 Marilyn Huang 5 Anna Kryzhanivska 6 Iurie Bulat 7 Tarek M Meniawy 8 Andrea Bagameri 9 Edward W Wang 10 Bernard Doger de Speville Uribe 11 Roberto Hegg 12 Waldo Ortuzar Feliu 13 Marek Ancukiewicz 13 Iwona Lugowska 14 
Affiliations
  • PMID: 34932394
  •     39 References
  •     2 citations

Abstract

Purpose: Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial (ClinicalTrials.gov identifier: NCT03495882) evaluated the combination of balstilimab plus zalifrelimab in patients with recurrent and/or metastatic cervical cancer who relapsed after prior platinum-based therapy.

Patients And Methods: Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg once every 6 weeks, for up to 24 months. The primary end point was objective response rate (ORR, RECIST version 1.1, assessed by independent central review). Secondary end points included duration of response, safety and tolerability, and survival.

Results: In total, 155 women (median age, 50 years [range, 24-76 years]) were enrolled and treated with balstilimab plus zalifrelimab; 125 patients had measurable disease at baseline and one prior line of platinum-based therapy in the advanced setting, and these patients constituted the efficacy-evaluable population. The median follow-up was 21 months. The confirmed ORR was 25.6% (95% CI, 18.8 to 33.9), including 10 complete responders and 22 partial responders, with median duration of response not reached (86.5%, 75.5%, and 64.2% at 6, 9, and 12 months, respectively). The ORRs were 32.8% and 9.1% in patients with programmed death ligand-1-positive and programmed death ligand-1-negative tumors, respectively. For patients with squamous cell carcinoma, the ORR was 32.6%. The overall disease control rate was 52% (95% CI, 43.3 to 60.6). Hypothyroidism (14.2%) and hyperthyroidism (7.1%) were the most common immune-mediated adverse events.

Conclusion: Promising and durable clinical activity, with favorable tolerability, was seen in this largest trial to date evaluating dual programmed death-1/cytotoxic T-lymphocyte-associated antigen-4 blockade in patients with recurrent and/or metastatic cervical cancer. Further investigation of the balstilimab and zalifrelimab combination in this setting is continuing.

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients.
Shi Zhou, Samrat Khanal, Haijun Zhang.
Ther Clin Risk Manag, 2019 Feb 19; 15. PMID: 30774357    Free PMC article.
Review.
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Cheng Xu, Yu-Pei Chen, +12 authors, Jun Ma.
BMJ, 2018 Nov 10; 363. PMID: 30409774    Free PMC article.
Highly Cited. Systematic Review.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.
Jingjie Chen, Shengnan Li, +8 authors, Yingying Tang.
World J Surg Oncol, 2020 Jul 06; 18(1). PMID: 32620130    Free PMC article.
Systematic Review.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Douglas B Johnson, Justin M Balko, +29 authors, Javid J Moslehi.
N Engl J Med, 2016 Nov 03; 375(18). PMID: 27806233    Free PMC article.
Highly Cited.
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.
Joseph E Grossman, Divya Vasudevan, Cailin E Joyce, Manuel Hildago.
Oncogene, 2021 Jan 28; 40(8). PMID: 33500548    Free PMC article.
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C Marth, F Landoni, +4 authors, ESMO Guidelines Committee.
Ann Oncol, 2017 Sep 09; 28(suppl_4). PMID: 28881916
Highly Cited.
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
David M O'Malley, Ana Oaknin, +15 authors, Isabelle Ray-Coquard.
Gynecol Oncol, 2021 Aug 29; 163(2). PMID: 34452745
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, F Stephen Hodi, Jedd D Wolchok.
N Engl J Med, 2015 Sep 24; 373(13). PMID: 26398076
Highly Cited.
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Ines Pires da Silva, Tasnia Ahmed, +25 authors, Georgina V Long.
Lancet Oncol, 2021 May 15; 22(6). PMID: 33989557
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Stergios Boussios, Esmeralda Seraj, +7 authors, George Pentheroudakis.
Crit Rev Oncol Hematol, 2016 Dec 10; 108. PMID: 27931835
Review.
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Charlotte Roach, Nancy Zhang, +7 authors, Karina Kulangara.
Appl Immunohistochem Mol Morphol, 2016 Jun 23; 24(6). PMID: 27333219    Free PMC article.
Highly Cited.
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
David M O'Malley, Leslie M Randall, +10 authors, Bradley J Monk.
Future Oncol, 2021 Aug 20; 17(26). PMID: 34409858
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Robert L Coleman, Domenica Lorusso, +21 authors, innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators.
Lancet Oncol, 2021 Apr 13; 22(5). PMID: 33845034
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Laura C Cappelli, Anna Kristina Gutierrez, +10 authors, Clifton O Bingham.
Ann Rheum Dis, 2016 Jun 17; 76(1). PMID: 27307501    Free PMC article.
Highly Cited.
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, +8 authors, James P Allison.
Cell, 2017 Aug 15; 170(6). PMID: 28803728    Free PMC article.
Highly Cited.
Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
Aleksandra Popovic, Elizabeth M Jaffee, Neeha Zaidi.
J Clin Invest, 2018 Aug 02; 128(8). PMID: 30067248    Free PMC article.
Highly Cited. Review.
Improved survival with bevacizumab in advanced cervical cancer.
Krishnansu S Tewari, Michael W Sill, +9 authors, Bradley J Monk.
N Engl J Med, 2014 Feb 21; 370(8). PMID: 24552320    Free PMC article.
Highly Cited.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, +30 authors, CheckMate 214 Investigators.
N Engl J Med, 2018 Mar 22; 378(14). PMID: 29562145    Free PMC article.
Highly Cited.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, +17 authors, Thierry André.
J Clin Oncol, 2018 Jan 23; 36(8). PMID: 29355075
Highly Cited.
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Jinfang Zhang, Fabin Dang, Junming Ren, Wenyi Wei.
Trends Biochem Sci, 2018 Oct 06; 43(12). PMID: 30287140    Free PMC article.
Review.
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock.
Mol Cancer Ther, 2015 Feb 20; 14(4). PMID: 25695955
Highly Cited. Review.
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Omid Kooshkaki, Afshin Derakhshani, +6 authors, Behzad Baradaran.
Int J Mol Sci, 2020 Jun 26; 21(12). PMID: 32580338    Free PMC article.
Review.
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Vivek Kumar, Neha Chaudhary, +3 authors, Abhinav B Chandra.
Front Pharmacol, 2017 Feb 24; 8. PMID: 28228726    Free PMC article.
Highly Cited. Review.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2019 Sep 29; 381(16). PMID: 31562797
Highly Cited.
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Hyun Cheol Chung, Willeke Ros, +9 authors, Alexandra Leary.
J Clin Oncol, 2019 Apr 04; 37(17). PMID: 30943124
Highly Cited.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +30 authors, James Larkin.
N Engl J Med, 2017 Sep 12; 377(14). PMID: 28889792    Free PMC article.
Highly Cited.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, +23 authors, Suresh S Ramalingam.
N Engl J Med, 2019 Sep 29; 381(21). PMID: 31562796
Highly Cited.
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.
Marc Arbyn, Elisabete Weiderpass, +4 authors, Freddie Bray.
Lancet Glob Health, 2019 Dec 10; 8(2). PMID: 31812369    Free PMC article.
Highly Cited.
PD-1/PD-L1 Inhibitors in Cervical Cancer.
Yuncong Liu, Li Wu, +6 authors, You Lu.
Front Pharmacol, 2019 Feb 19; 10. PMID: 30774597    Free PMC article.
Review.
Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Lindsey E Minion, Krishnansu S Tewari.
Gynecol Oncol, 2018 Apr 19; 148(3). PMID: 29666026    Free PMC article.
Review.
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
Stephanie Lheureux, Marcus O Butler, +22 authors, Amit M Oza.
JAMA Oncol, 2017 Nov 18; 4(7). PMID: 29145543    Free PMC article.
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Chunyan Hao, Jinhui Tian, +3 authors, Bingdong Zhu.
Medicine (Baltimore), 2017 Jun 29; 96(26). PMID: 28658143    Free PMC article.
Systematic Review.
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Ozlen Saglam, Jose Conejo-Garcia.
Integr Cancer Sci Ther, 2018 Jun 30; 5(2). PMID: 29955379    Free PMC article.
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Frank Stephen Hodi, Vanna Chiarion-Sileni, +16 authors, Jedd D Wolchok.
Lancet Oncol, 2018 Oct 27; 19(11). PMID: 30361170
Highly Cited.
Immunotherapy for Uterine Cervical Cancer.
Masahiro Kagabu, Takayuki Nagasawa, +4 authors, Tsukasa Baba.
Healthcare (Basel), 2019 Sep 20; 7(3). PMID: 31533297    Free PMC article.
Review.
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Anand Rotte.
J Exp Clin Cancer Res, 2019 Jun 15; 38(1). PMID: 31196207    Free PMC article.
Highly Cited. Review.
The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways.
Michael J Birrer, Keiichi Fujiwara, +4 authors, Isabelle Ray-Coquard.
Front Oncol, 2022 Mar 15; 12. PMID: 35280818    Free PMC article.
Review.
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Mengling Wu, Qianrui Huang, +4 authors, Yong Xia.
J Hematol Oncol, 2022 Mar 14; 15(1). PMID: 35279217    Free PMC article.
Review.